<DOC>
	<DOCNO>NCT02316756</DOCNO>
	<brief_summary>This first human ( FIH ) , double-blind , sponsor open , placebo-control trial examine safety , tolerability , pharmacokinetics pharmacodynamics follow single ascend dos PF-06648671 healthy subject .</brief_summary>
	<brief_title>A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject non childbearing potential BMI 17.5 30.5 kg/m2 total body weight &gt; 50 kg ( 110 lb ) Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drg allergy , exclude untreated asymptomatic , seasonal allergy time dose ) ; Treatment investigational drug within 30 day ( determined local requirement ) 5 halflives precede first dose study medication ( whichever longer ) Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgement investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 1 , Single-Dose Escalation , Double Blind , Placebo-Controlled , Safety , Tolerability , Pharmacokinetics , Pharmacodynamics , PF-06648671 , Plasma Abeta</keyword>
</DOC>